Please select the arm or intervention descriptions that belong to the clinical trial below.
Title: A Randomized, Double-blind, Placebo-controlled, Multiple-dose Study to Evaluate the Safety, Tolerability, and Efficacy of AMG 827 in Subjects With Psoriasis
Brief Summary: The study evaluated the efficacy of AMG 827 compared with placebo as measured by the percent of improvement in PASI score at week 12.


Options:
A: Arm Label: 140 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 140 mg SC | Arm Label: 70 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 70 mg SC | Arm Label: 280 mg SC; Type: EXPERIMENTAL; Interventions: Drug: 280 mg SC | Arm Label: 210 mg SC; Type: PLACEBO_COMPARATOR; Interventions: Drug: 210 mg SC | Arm Label: Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo | Intervention Type: DRUG; Name: 70 mg SC; Assigned to Arm(s): 70 mg SC | Intervention Type: DRUG; Name: 210 mg SC; Assigned to Arm(s): 210 mg SC | Intervention Type: DRUG; Name: 140 mg SC; Assigned to Arm(s): 140 mg SC | Intervention Type: DRUG; Name: 280 mg SC; Assigned to Arm(s): 280 mg SC | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): Placebo
B: Arm Label: AIN457 150mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: Placebo; Type: PLACEBO_COMPARATOR; Interventions: Drug: Placebo | Arm Label: Etanercept; Type: ACTIVE_COMPARATOR; Interventions: Drug: Placebo, Drug: etanercept | Arm Label: AIN457 150mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Arm Label: AIN457 300mg from Placebo; Type: EXPERIMENTAL; Interventions: Drug: Placebo, Drug: secukinumab (AIN457) | Intervention Type: DRUG; Name: Placebo; Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo, Etanercept, Placebo | Intervention Type: DRUG; Name: secukinumab (AIN457); Assigned to Arm(s): AIN457 150mg, AIN457 150mg from Placebo, AIN457 300mg, AIN457 300mg from Placebo | Intervention Type: DRUG; Name: etanercept; Assigned to Arm(s): Etanercept
C: Arm Label: Immediate Methotrexate Cessation; Type: EXPERIMENTAL; Interventions: Drug: Ustekinumab | Arm Label: Gradual Reduction of Methotrexate; Type: ACTIVE_COMPARATOR; Interventions: Drug: Ustekinumab, Drug: Methotrexate | Intervention Type: DRUG; Name: Ustekinumab; Assigned to Arm(s): Gradual Reduction of Methotrexate, Immediate Methotrexate Cessation | Intervention Type: DRUG; Name: Methotrexate; Assigned to Arm(s): Gradual Reduction of Methotrexate
D: Arm Label: Secukinumab 150 mg load (Group 1); Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Secukinumab 150 mg no load (Group 2); Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Secukinumab 300 mg load (Group 3); Type: EXPERIMENTAL; Interventions: Biological: Secukinumab | Arm Label: Placebo arm 1 (Group 4); Type: PLACEBO_COMPARATOR; Interventions: Biological: Secukinumab | Arm Label: Placebo arm 2 (Group 4); Type: PLACEBO_COMPARATOR; Interventions: Biological: Secukinumab | Intervention Type: BIOLOGICAL; Name: Secukinumab; Assigned to Arm(s): Placebo arm 1 (Group 4), Placebo arm 2 (Group 4), Secukinumab 150 mg load (Group 1), Secukinumab 150 mg no load (Group 2), Secukinumab 300 mg load (Group 3)

Answer: A